Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BLM | P54132 | 2/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.67 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.67 |
| ▸ | VCP | P55072 | 1/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.67 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.67 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.50 |
| ▸ | HPRT1 | P00492 | 8/20 | 0.46 |
| ▸ | PNP | P00491 | 2/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | EDNRA | P25101 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | HBB | P68871 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ganciclovir SCHEMBL147839 | 0.99 | BLM (0.65) | BLMKMT2AMEN1ALDH1A1LMNA | |
| SCHEMBL15045889 | 0.92 | BLM (0.57) | BLMKMT2AMEN1ALDH1A1LMNA | |
| SCHEMBL15257621 | 0.90 | KMT2A (0.55) | BLMKMT2AMEN1ALDH1A1LMNA | |
| SCHEMBL15531833 | 0.88 | MEN1 (0.53) | BLMKMT2AMEN1ALDH1A1LMNA | |
| SCHEMBL18190768 | 0.88 | KMT2A (0.52) | BLMKMT2AMEN1ALDH1A1LMNA | |
| SCHEMBL19236311 | 0.85 | PDE3A (0.56) | BLMKMT2AMEN1ALDH1A1LMNA | |
| Valganciclovir SCHEMBL28996 | 0.85 | PDE3A (0.74) | BLMKMT2AMEN1ALDH1A1LMNA | |
| (S)-Valganciclovir SCHEMBL28997 | 0.85 | PDE3A (0.74) | BLMKMT2AMEN1ALDH1A1LMNA | |
| SCHEMBL4281488 | 0.84 | PDE3A (0.51) | BLMKMT2AMEN1ALDH1A1LMNA | |
| Valganciclovir SCHEMBL23225 | 0.84 | PDE3A (0.73) | BLMKMT2AMEN1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 68931 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144879-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | AI-BIOPHARMA (FR) | 2026-05-28 | — | — | US | claimed |
| US-20260144816-A1 | COMPOSITIONS AND METHODS FOR TREATING DEMENTIA | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2026-05-28 | — | — | US | claimed |
| EP-4748448-A2 | USE OF MARIBAVIR FOR THE TREATMENT OF AND TREATMENT REGIMENS THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2026-05-27 | — | — | EP | claimed |
| US-12637688-B2 | DNA construct for diagnosing and treating cancer | CNCURE BIOTECH INC. (KR) | 2026-05-26 | — | — | US | claimed |
| US-20260137669-A1 | NOVEL ENANTIOMERS OF A SERIES OF ANTIVIRAL COMPOUNDS | INNOVATIVE MOLECULES GMBH (DE) | 2026-05-21 | — | — | US | claimed |
| WO-2026107113-A1 | MODIFIED CELLS FOR PROGRAMMING EXTRA ENVELOPED VIRUSES (EEVs) AND THEIR USE FOR PRODUCING THE EEVs, THE PROGRAMMED EEVs AND USES THEREOF | CALIDI BIOTHERAPEUTICS (NEVADA), INC. (US) | 2026-05-21 | — | — | WO | claimed |
| WO-2026107010-A1 | MODULATION OF GENE EXPRESSION FOR GENE THERAPY | THE METHODIST HOSPITAL (US) | 2026-05-21 | — | — | WO | claimed |
| EP-4094767-B1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | UNIV EMORY (US) | 2026-05-20 | — | — | EP | claimed |
| US-12631653-B2 | Methods for diagnosing and treating uveitis | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2026-05-19 | — | — | US | claimed |
| WO-2025136820-A9 | POLY-ANTIGEN CYTOKINE-RECEPTOR COMPLEXES (PACCS), COMPOSITIONS, AND METHODS OF USE | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2026-05-15 | — | — | WO | claimed |
| WO-1991018914-A1 | SYNTHESIS OF GLYCEROL DI- AND TRIPHOSPHATE DERIVATIVES | VICAL, INC. (US) | 1991-12-12 | — | — | WO | claimed |
| WO-1991018611-A1 | DIAGNOSIS AND TREATMENT OF VIRAL HEPATITIS | HEM RESEARCH, INC. (US) | 1991-12-12 | — | — | WO | claimed |
| EP-0457326-A1 | Antiviral agents | SYNTEX (U.S.A.) INC. (US) | 1991-11-21 | — | — | EP | claimed |
| EP-0454773-A1 | NOVEL PRODRUG DERIVATIVES OF BIOLOGICALLY ACTIVE AGENTS CONTAINING HYDROXYL GROUPS OR NH-ACIDIC GROUPS | Bundgaard, Hans (DK) | 1991-11-06 | — | — | EP | claimed |
| US-5049389-A | Non-phospholipd lipid, delivery by inhalation | LIPOSOME TECHNOLOGY, INC. (US) | 1991-09-17 | — | — | US | claimed |
| WO-1991008743-A1 | CIRCUMVENTION OF HUMAN TUMOR DRUG RESISTANCE | CITY OF HOPE (US) | 1991-06-27 | — | — | WO | claimed |
| WO-1991007180-A1 | CIRCUMVENTION OF HUMAN TUMOR DRUG RESISTANCE | CITY OF HOPE (US) | 1991-05-30 | — | — | WO | claimed |
| WO-1990008128-A1 | NOVEL PRODRUG DERIVATIVES OF BIOLOGICALLY ACTIVE AGENTS CONTAINING HYDROXYL GROUPS OR NH-ACIDIC GROUPS | BUNDGAARD HANS (DK) | 1990-07-26 | — | — | WO | claimed |
| WO-1990006775-A1 | A NOVEL NONPHOSPHOLIPID LIPOSOME COMPOSITION FOR SUSTAINED RELEASE OF DRUGS | LIPOSOME TECHNOLOGY, INC. (US) | 1990-06-28 | — | — | WO | claimed |
| EP-0371366-A1 | Antiviral agents | SYNTEX (U.S.A.) INC. (US) | 1990-06-06 | — | — | EP | claimed |